Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice

Open access
Yue, Wenwen, Chen, Liang, Yu, Luodan, Zhou, Bangguo, Yin, Haohao, Ren, Weiwei, Liu, Chang, Guo, Lehang, Zhang, Yifeng, Sun, Liping, Zhang, Kun, Xu, Huixiong, Chen, Yu · 2019 · Nature Communications

Abstract

Combined checkpoint blockade (e.g., PD1/PD-L1) with traditional clinical therapies can be hampered by side effects and low tumour-therapeutic outcome, hindering broad clinical translation. Here we report a combined tumour-therapeutic modality based on integrating nanosonosensitizers-augmented noninvasive sonodynamic therapy (SDT) with checkpoint-blockade immunotherapy. All components of the nanosonosensitizers (HMME/R837@Lip) are clinically approved, wherein liposomes act as carriers to co-encapsulate sonosensitizers (hematoporphyrin monomethyl ether (HMME)) and immune adjuvant (imiquimod (R837)). Using multiple tumour models, we demonstrate that combining nanosonosensitizers-augmented SDT with anti-PD-L1 induces an anti-tumour response, which not only arrests primary tumour progression, but also prevents lung metastasis. Furthermore, the combined treatment strategy offers a long-term immunological memory function, which can protect against tumour rechallenge after elimination of the initial tumours. Therefore, this work represents a proof-of-concept combinatorial tumour therapeutics based on noninvasive tumours-therapeutic modality with immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09760-3

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The design principle of nanosonosensitiser-augmented synergistic SDT and immunotherapy. Schematic illustration of antitumour immune responses induced by combined noninvasive SDT with immune-adjuvant-contained nanosonosensitisers and checkpoint blockade for effective cancer immunotherapy
Fig. 1 The design principle of nanosonosensitiser-augmented synergistic SDT and immunotherapy. Schematic illustration of antitumour immune responses induced by combined noninvasive SDT with immune-adjuvant-contained nanosonosensitisers and checkpoint blockade for effective cancer immunotherapyCC BY · PubMed Central
Fig. 2 Synthesis and characterisations of the composite nanosonosensitisers. a Schematic illustration of the construction of HMME/R837@Lip nanosonosensitisers and their microstructures; b TEM image showing the quasi-spherical morphology of HMME/R837@Lip with high dispersity (scale bar = 100 nm); c hydrodynamic diameters of HMME/R837@Lip nanosonosensitisers in PBS as measured by DLS; d UV-vis absorbance spectra of Lip, HMME, HMME@Lip and HMME/R837@Lip, indicating the successful encapsulation of HMME into the nano-liposome; e zeta potential of Lip, HMME@Lip and HMME/R837@Lip, error bars are based on SD (n = 3); f scheme of US-triggered 1O2 production as assisted by HMME/R837@Lip; g ESR spectra of HMME/R837@Lip with or without US treatment; h time-dependent DPBF absorption spectra in the presence of HMME/R837@Lip under US irradiation for varied durations
Fig. 2 Synthesis and characterisations of the composite nanosonosensitisers. a Schematic illustration of the construction of HMME/R837@Lip nanosonosensitisers and their microstructures; b TEM image showing the quasi-spherical morphology of HMME/R837@Lip with high dispersity (scale bar = 100 nm); c hydrodynamic diameters of HMME/R837@Lip nanosonosensitisers in PBS as measured by DLS; d UV-vis absorbance spectra of Lip, HMME, HMME@Lip and HMME/R837@Lip, indicating the successful encapsulation of HMME into the nano-liposome; e zeta potential of Lip, HMME@Lip and HMME/R837@Lip, error bars are based on SD (n = 3); f scheme of US-triggered 1O2 production as assisted by HMME/R837@Lip; g ESR spectra of HMME/R837@Lip with or without US treatment; h time-dependent DPBF absorption spectra in the presence of HMME/R837@Lip under US irradiation for varied durationsCC BY · PubMed Central
Fig. 3 In vitro toxicity of HMME/R837@Lip upon US irradiation against 4T1 cancer cells and stimulation of in vitro immune response. a CLSM images of 4T1 cells stained with DCFH-DA after different treatments: control (without any treatment), HMME@Lip only, HMME/R837@Lip only, US only, HMME@Lip combined with US irradiation and HMME/R837@Lip combined with US irradiation (scale bar = 20 μm); b CLSM images of 4T1 cells stained with Calcein-AM and PI after various treatments: control (without any treatment), HMME@Lip only, HMME/R837@Lip only, US only, HMME@Lip combined with US irradiation and HMME/R837@Lip combined with US irradiation (scale bar = 20 μm); c the design scheme of the transwell system experiment. 4T1 cells and their residues were placed in the upper compartment and DCs were cultured in the lower compartment; d the percentage of mature DCs (CD11c+CD80+CD86+) was analysed by flow cytometry after different treatments for 20 h in the transwell system; e–g quantification of the level of DC maturation (e) and the secretion of IL-6 (f) and TNF-α (g) in DC suspensions. Data are expressed as means ± SD (n = 3). Statistical significances were calculated via Student’s t test, *p < 0.05, **p < 0.01 and ***p < 0.001
Fig. 3 In vitro toxicity of HMME/R837@Lip upon US irradiation against 4T1 cancer cells and stimulation of in vitro immune response. a CLSM images of 4T1 cells stained with DCFH-DA after different treatments: control (without any treatment), HMME@Lip only, HMME/R837@Lip only, US only, HMME@Lip combined with US irradiation and HMME/R837@Lip combined with US irradiation (scale bar = 20 μm); b CLSM images of 4T1 cells stained with Calcein-AM and PI after various treatments: control (without any treatment), HMME@Lip only, HMME/R837@Lip only, US only, HMME@Lip combined with US irradiation and HMME/R837@Lip combined with US irradiation (scale bar = 20 μm); c the design scheme of the transwell system experiment. 4T1 cells and their residues were placed in the upper compartment and DCs were cultured in the lower compartment; d the percentage of mature DCs (CD11c+CD80+CD86+) was analysed by flow cytometry after different treatments for 20 h in the transwell system; e–g quantification of the level of DC maturation (e) and the secretion of IL-6 (f) and TNF-α (g) in DC suspensions. Data are expressed as means ± SD (n = 3). Statistical significances were calculated via Student’s t test, *p < 0.05, **p < 0.01 and ***p < 0.001CC BY · PubMed Central
Fig. 4 In vivo HMME/R837@Lip-augmented SDT for inducing cell apoptosis and/or necrosis, promoting DC maturation and stimulating the expression of proinflammatory cytokines. a Schematic illustration of the experiment design to assess the in vivo sonotoxicity and the immune responses as triggered by HMME/R837@Lip-augmented SDT; b, c in vivo apoptosis and/or necrosis of the tumour induced by HMME/R837@Lip-augmented SDT, as shown by H&E staining (scale bar = 100 μm) and TUNEL assay (scale bar = 50 μm); d, e DC maturation in the tumour-draining lymph nodes induced by HMME/R837@Lip-augmented SDT on mice bearing 4T1 tumours, as assessed by flow cytometry after staining with CD11c, CD80, CD86 and live dead; f–h cytokine levels of TNF-α, IL-6 and IL-12p70 in sera from mice isolated from 24 to 72 h after HMME/R837@Lip-agumented SDT treatment. Data are expressed as means ± SD (n = 3). Statistical significances were calculated via Student’s t test, *p < 0.05, **p < 0.01
Fig. 4 In vivo HMME/R837@Lip-augmented SDT for inducing cell apoptosis and/or necrosis, promoting DC maturation and stimulating the expression of proinflammatory cytokines. a Schematic illustration of the experiment design to assess the in vivo sonotoxicity and the immune responses as triggered by HMME/R837@Lip-augmented SDT; b, c in vivo apoptosis and/or necrosis of the tumour induced by HMME/R837@Lip-augmented SDT, as shown by H&E staining (scale bar = 100 μm) and TUNEL assay (scale bar = 50 μm); d, e DC maturation in the tumour-draining lymph nodes induced by HMME/R837@Lip-augmented SDT on mice bearing 4T1 tumours, as assessed by flow cytometry after staining with CD11c, CD80, CD86 and live dead; f–h cytokine levels of TNF-α, IL-6 and IL-12p70 in sera from mice isolated from 24 to 72 h after HMME/R837@Lip-agumented SDT treatment. Data are expressed as means ± SD (n = 3). Statistical significances were calculated via Student’s t test, *p < 0.05, **p < 0.01CC BY · PubMed Central
Fig. 5 Synergistic nanosonosensitiser-augmented SDT and immunotherapy for in vivo suppression of mimic distant tumours in a subcutaneous tumour model. a Schematic showing the experiment design for in vivo evaluations. Mice bearing 4T1 subcutaneous tumours on both sides were used in this experiment. Tumours on the right side of the check were designed as “primary tumour” for SDT, and those on the left side were set as “mimic distant tumours” without SDT; b in vivo fluorescence images to reveal the biodistribution of HMME/R837@Lip post i.v. injection into 4T1-tumour-bearing mice at the indicated time points. Yellow arrows indicate tumours; c the accumulation curve of HMME/R837@Lip in the tumour tissue by measuring the fluorescence intensity of tumours at different time points post i.v. injection, error bars are based on SD (n = 3); d the ex vivo fluorescence image of major organs and tumour dissected from the mouse 24 and 48 h post injection and (e) quantification analysis of the tissue content of HMME/R837@Lip by testing the corresponding fluorescence intensity; data are expressed as means ± SD (n = 3); f, h primary (f) and distant (h) tumours growth curves of different groups of tumour-bearing mice after various treatments as indicated in the figure. Error bars are based on SD (n = 5); average weights of g primary and i distant tumours at the end of treatment; time-dependent body temperature (j) and weight (k) surveillance of mice (n = 5) after different treatments. Statistical significances were calculated via Student’s t test, **p < 0.01 and ***p < 0.001
Fig. 5 Synergistic nanosonosensitiser-augmented SDT and immunotherapy for in vivo suppression of mimic distant tumours in a subcutaneous tumour model. a Schematic showing the experiment design for in vivo evaluations. Mice bearing 4T1 subcutaneous tumours on both sides were used in this experiment. Tumours on the right side of the check were designed as “primary tumour” for SDT, and those on the left side were set as “mimic distant tumours” without SDT; b in vivo fluorescence images to reveal the biodistribution of HMME/R837@Lip post i.v. injection into 4T1-tumour-bearing mice at the indicated time points. Yellow arrows indicate tumours; c the accumulation curve of HMME/R837@Lip in the tumour tissue by measuring the fluorescence intensity of tumours at different time points post i.v. injection, error bars are based on SD (n = 3); d the ex vivo fluorescence image of major organs and tumour dissected from the mouse 24 and 48 h post injection and (e) quantification analysis of the tissue content of HMME/R837@Lip by testing the corresponding fluorescence intensity; data are expressed as means ± SD (n = 3); f, h primary (f) and distant (h) tumours growth curves of different groups of tumour-bearing mice after various treatments as indicated in the figure. Error bars are based on SD (n = 5); average weights of g primary and i distant tumours at the end of treatment; time-dependent body temperature (j) and weight (k) surveillance of mice (n = 5) after different treatments. Statistical significances were calculated via Student’s t test, **p < 0.01 and ***p < 0.001CC BY · PubMed Central
Fig. 6 Antitumour effect of HMME/R837@Lip-augmented SDT plus anti-PD-L1 immunotherapy in orthotopic tumour models. a Schematic illustration of HMME/R837@Lip-augmented SDT and anti-PD-L1 combination therapy to inhibit tumour growth at the distant sites on orthotopic tumour models; b in vivo fluorescence images to study the biodistribution of HMME/R837@Lip post i.v. injection in 4T1 orthotopic tumour-bearing mice at the indicated time points. Yellow arrows indicate tumours; c the accumulation curve of HMME/R837@Lip in the tumour tissue by measuring the fluorescence of tumours at different time points post i.v. injection, error bars are based on SD (n = 3); d–i primary (d) and distant (g) tumour-growth curves of different groups of orthotopic tumour-bearing mice after various treatments as indicated in the figure. Error bars are based on SD (n = 5); average weights of primary (e) and distant (h) tumours at the end of treatments; photographs of excised primary (f) and distant (i) tumours at the end of treatments; j in vivo bioluminescence images tracking the spreading and growth of i.v. injected fLuc-4T1 tumour cells in the mice after different treatments; k representative photographs to show the gross appearance of tumour nodules in the lungs; l the numbers of lung nodules were counted under anatomy microscope. Values are means ± standard error (SE) (n = 5); m representative haematoxylin and eosin staining analysis of the lung metastasis. Scale bar = 2 mm. Statistical significances were calculated via Student’s t test, *p < 0.05, ** p < 0.01 and ***p < 0.001
Fig. 6 Antitumour effect of HMME/R837@Lip-augmented SDT plus anti-PD-L1 immunotherapy in orthotopic tumour models. a Schematic illustration of HMME/R837@Lip-augmented SDT and anti-PD-L1 combination therapy to inhibit tumour growth at the distant sites on orthotopic tumour models; b in vivo fluorescence images to study the biodistribution of HMME/R837@Lip post i.v. injection in 4T1 orthotopic tumour-bearing mice at the indicated time points. Yellow arrows indicate tumours; c the accumulation curve of HMME/R837@Lip in the tumour tissue by measuring the fluorescence of tumours at different time points post i.v. injection, error bars are based on SD (n = 3); d–i primary (d) and distant (g) tumour-growth curves of different groups of orthotopic tumour-bearing mice after various treatments as indicated in the figure. Error bars are based on SD (n = 5); average weights of primary (e) and distant (h) tumours at the end of treatments; photographs of excised primary (f) and distant (i) tumours at the end of treatments; j in vivo bioluminescence images tracking the spreading and growth of i.v. injected fLuc-4T1 tumour cells in the mice after different treatments; k representative photographs to show the gross appearance of tumour nodules in the lungs; l the numbers of lung nodules were counted under anatomy microscope. Values are means ± standard error (SE) (n = 5); m representative haematoxylin and eosin staining analysis of the lung metastasis. Scale bar = 2 mm. Statistical significances were calculated via Student’s t test, *p < 0.05, ** p < 0.01 and ***p < 0.001CC BY · PubMed Central
Fig. 7 HMME/R837@Lip-augmented SDT plus anti-PD-L1 therapy activating systematic antitumour immunity. a–c Representative flow-cytometry plots showing the tumour-infiltrating leucocyte cells, including CD45+ cells (CD45+), CD8+ T cells (CD45+CD3e+CD8+) and CD4+ FoxP3+ T cells (CD45+CD3e+CD4+ FoxP3+) in mimic distant tumours; d absolute quantification of the CD45+ cells, CD8+ T cells and CD4+ FoxP3+ regulatory T cells (Treg) in mimic distant tumours (gating on CD3+ cells), error bars are based on SD (n = 3); e CD45+ cells: Treg ratios and CD8+cells: Treg ratios in the distant tumours after various treatments to remove the first tumour. Values are mean ± SD (n = 3); f representative CLSM images of the mimic distant tumours after immunofluorescence staining (scale bar = 50 μm). Statistical significances were calculated via Student’s t test or Mann–Whitney U test. NS not significant. *p < 0.05, **p < 0.01 and ***p < 0.001
Fig. 7 HMME/R837@Lip-augmented SDT plus anti-PD-L1 therapy activating systematic antitumour immunity. a–c Representative flow-cytometry plots showing the tumour-infiltrating leucocyte cells, including CD45+ cells (CD45+), CD8+ T cells (CD45+CD3e+CD8+) and CD4+ FoxP3+ T cells (CD45+CD3e+CD4+ FoxP3+) in mimic distant tumours; d absolute quantification of the CD45+ cells, CD8+ T cells and CD4+ FoxP3+ regulatory T cells (Treg) in mimic distant tumours (gating on CD3+ cells), error bars are based on SD (n = 3); e CD45+ cells: Treg ratios and CD8+cells: Treg ratios in the distant tumours after various treatments to remove the first tumour. Values are mean ± SD (n = 3); f representative CLSM images of the mimic distant tumours after immunofluorescence staining (scale bar = 50 μm). Statistical significances were calculated via Student’s t test or Mann–Whitney U test. NS not significant. *p < 0.05, **p < 0.01 and ***p < 0.001CC BY · PubMed Central
Fig. 8 Anticancer activity of HMME/R837@Lip-augmented SDT plus anti-PD-L1 therapy in murine colorectal cancer models. a Schematic illustration of the experiment design to assess the antitumour immune responses against mimic distant tumours and the immunological memory response triggered by HMME/R837@Lip-augmented SDT and anti-PD-L1 combination therapy; b, c primary (b) and mimic distant (c) tumour growth curves of different groups of tumour-bearing mice after various treatments as indicated in the figure. Error bars are based on SD (n = 6); d time-dependent body-weight surveillance of mice (n = 6) after different treatments; e morbidity-free survival of mice after different treatments (n = 6); f tumour-growth curves of the rechallenged tumours in the corresponding groups were stopped when the first mouse died. Error bars are based on SE (n = 8); g morbidity-free survival of mice after the indicated treatment (n = 8), statistical significance was calculated via the log-rank (Mantel–Cox) test; h TNF-α and IFN-γ levels in serum isolated from mice of the treatment group and native group 7 days after the second tumour was introduced. Error bars are based on SE (n = 5 for the native group, n = 4 for the combined treatment group); i representative flow-cytometry plots of splenic lymphocytes of CT26 tumour-bearing mice treated with the combined immunotherapy at day 29 right before mice rechallenged with the secondary tumours (gating on CD3+ cells); j, k absolute quantification of naive T cells, TCM and TEM in the spleen. TCM central memory T cells, TEM effector memory T cells. Error bars are based on SD (n = 4). Statistical significances were calculated via Student’s t test. *p < 0.05, **p < 0.01 and ***p < 0.001
Fig. 8 Anticancer activity of HMME/R837@Lip-augmented SDT plus anti-PD-L1 therapy in murine colorectal cancer models. a Schematic illustration of the experiment design to assess the antitumour immune responses against mimic distant tumours and the immunological memory response triggered by HMME/R837@Lip-augmented SDT and anti-PD-L1 combination therapy; b, c primary (b) and mimic distant (c) tumour growth curves of different groups of tumour-bearing mice after various treatments as indicated in the figure. Error bars are based on SD (n = 6); d time-dependent body-weight surveillance of mice (n = 6) after different treatments; e morbidity-free survival of mice after different treatments (n = 6); f tumour-growth curves of the rechallenged tumours in the corresponding groups were stopped when the first mouse died. Error bars are based on SE (n = 8); g morbidity-free survival of mice after the indicated treatment (n = 8), statistical significance was calculated via the log-rank (Mantel–Cox) test; h TNF-α and IFN-γ levels in serum isolated from mice of the treatment group and native group 7 days after the second tumour was introduced. Error bars are based on SE (n = 5 for the native group, n = 4 for the combined treatment group); i representative flow-cytometry plots of splenic lymphocytes of CT26 tumour-bearing mice treated with the combined immunotherapy at day 29 right before mice rechallenged with the secondary tumours (gating on CD3+ cells); j, k absolute quantification of naive T cells, TCM and TEM in the spleen. TCM central memory T cells, TEM effector memory T cells. Error bars are based on SD (n = 4). Statistical significances were calculated via Student’s t test. *p < 0.05, **p < 0.01 and ***p < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 607

Metadata

Authors
Yue, W., Chen, L., Yu, L., Zhou, B., Yin, H., Ren, W., Liu, C., Guo, L., Zhang, Y., Sun, L., Zhang, K., Xu, H., & Chen, Y.
Affiliations
  • Tongji University (CN)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Zhang, Kun
  • Chen, Yu
Venue
Nature Communications
Published
2019-05-02
Volume
10
Issue
1
Pages
2025-2025
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2942900492
Cited by
590
References
52
Citations by year
2026: 33 · 2025: 72 · 2024: 82 · 2023: 108 · 2022: 105 · 2021: 96 · 2020: 75 · 2019: 19
FWCI
26.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (2016YFA0203700, 81725008, 81671695, 81501474, 81501473, 51672303, 51722211, 81601501, 81601502, 81771836,)
  • Science and Technology Commission of Shanghai Municipality (18XD1404300, 14441900900, 16411971100)
  • Program of Shanghai Subject Chief Scientist (18XD1404300)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
sonodynamic therapy, hematoporphyrin monomethyl ether, imiquimod, liposomes, PD-L1 blockade, immune checkpoint blockade, lung metastasis, cancer immunotherapy, immunological memory, combination cancer therapy
MeSH terms
Antineoplastic Agents, Immunological, Imiquimod, Adjuvants, Immunologic, Animals, Combined Modality Therapy, Disease Models, Animal, Drug Screening Assays, Antitumor, Female, Hematoporphyrins, Humans, Immunotherapy, Liposomes, Mice, Inbred BALB C, Neoplasm Metastasis, Neoplasms, Ultrasonic Therapy, Treatment Outcome, Apoptosis, Cell Line, Tumor, Mice, Nanoparticles, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. https://app.cochat.ai/papers/10.1038/s41467-019-09760-3
The paper
Yue, W., Chen, L., Yu, L., Zhou, B., Yin, H., Ren, W., Liu, C., Guo, L., Zhang, Y., Sun, L., Zhang, K., Xu, H., & Chen, Y. (2019). Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nature Communications. https://doi.org/10.1038/s41467-019-09760-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.